HTS识别了具有新型支架的NUP98-KDM5A-PHD3域联体
Wenwei Lin1, P Jake Slavish1, Aaron H Phillips1
1†Department of Chemical Biology and Therapeutics, ‡Department of Structural Biology, and §Department of Pathology, St. Jude Children's Research Hospital, Memphis, Tennessee 38105, United States.
ACS medicinal chemistry letters
|June 25, 2025
概括
研究人员确定了针对NUP98-KDM5A融合蛋白的新型药物化合物,为治疗预后不佳的儿科急性髓性白血病 (AML) 提供了希望.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药物发现 药物发现 药物发现
背景情况:
- NUP98-KDM5A是一种瘤生成的融合蛋白,涉及到儿科急性髓性白血病 (AML).
- 患有NUP98-KDM5AAML的患者预后不佳,经常复发,需要新的治疗策略.
研究的目的:
- 确定抑制KDM5A-PHD3域与H3K4-(Me3) 的相互作用的新型小分子.
- 发现NUP98-KDM5A驱动的儿科AML的潜在治疗剂.
主要方法:
- 开发一种TR-FRET试验,用于选KDM5A-PHD3域连接体.
- 对超过60万个分子的化合物库进行选.
- 使用表面等离子体共振 (SPR) 和核磁共振 (NMR) 分析验证已识别的配体.
主要成果:
- 识别了几种具有独特支架的新型KDM5A-PHD3域联体.
- 已确认的配体包括CBL-0137,UNBS5162,BIX-01294和3--托克索弗拉.
- 这些化合物显示出向NUP98-KDM5A融合蛋白的潜力.
结论:
- 已识别的配体代表了开发针对NUP98-KDM5A儿科AML的向治疗的有希望的候选人.
- 这些新型化合物的进一步临床前开发是有必要的.
更多相关视频
05:08Application of I TASSER, trRosetta, UCSF Chimera, HADDOCK server, and HEX loria for De Novo and In Silico Design of Proteins
Published on: July 8, 2025
383
10:20Method for Identifying Small Molecule Inhibitors of the Protein-protein Interaction Between HCN1 and TRIP8b
Published on: November 11, 2016
8.6K
相关概念视频
Assembly of Signaling Complexes
6.0K
Multiprotein signaling complexes are formed in a dynamic process involving protein-protein interactions at the cytoplasmic domain of transmembrane receptors or enzymatic and non-enzymatic proteins associated with the receptor. These complexes ensure the activation and propagation of intracellular signals that regulate cell functions.
Interaction domains in cell signaling
Interaction domains recognize exposed features of their binding partners containing post-translationally modified sequences,...
Interaction domains in cell signaling
Interaction domains recognize exposed features of their binding partners containing post-translationally modified sequences,...
6.0K
Transducer Mechanism: Enzyme-Linked Receptors
2.8K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.8K
Ligand Binding and Linkage
4.9K
Allosteric proteins have more than one ligand binding site; the binding of a ligand to any of these sites influences the binding of ligands to the other sites. When a protein is allosteric, its binding sites are called coupled or linked. In the case of enzymes, the site that binds to the substrate is known as the active site and the other site is known as the regulatory site. When a ligand binds to the regulatory site, this leads to conformational changes in the protein that can influence...
4.9K
